Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
J&J shares survival data on KLK2 bispecific in prostate cancer
J&J reported 7.9 months of progression-free survival in hard-to-treat prostate cancer patients to fuel plans for further development.
Nick Paul Taylor
Jun 2, 2025 6:40am
Juri inks $210M T-cell engager deal with China biotech
May 27, 2025 6:00am
Biopsies illuminate potential of Candel's prostate cancer drug
May 22, 2025 6:57pm
Pathos AI's $365M series D to fund trial of Novo tumor drug
May 15, 2025 10:20am
MacroGenics pulls plug on ADC after seeing phase 2 survival data
Mar 21, 2025 7:15am
Monte Rosa's broad molecular glue degrader plan comes unstuck
Mar 20, 2025 10:07am
